European Medicines Agency recommends suspension of marketing approval with aprotinin-containing medicinal products for systemic useThe European Medicines Agency has recommended the suspension of marketing authorizations for all medicinal products for systemic use of aprotinin. Aprotinin is used for the blood loss and the need for transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery.
‘Our plan for the adoption of Cesium-131 internal radiation therapy see for the treatment of cancer throughout the body is on target with the growing number of physicians and institutions that treat the capability to quickly and powerfully cancers and their rates rates are enthusiastic. We expect further announcements ‘to make progress with respect to the use of this innovative technology in the near future, he said.. ISORAY CEO Dwight Babcock says the multi-institutional study is a major step forward in accelerating the treatment of adoption, ‘This study has enormous implications for Non Small Cell Lung Cancer patients worldwide This research gives us is important information shared be be with the growing number of already contacted already contacted us because cesium-131 internal radiation therapy of the reported rates of success in the treatment lung cancer are very high ‘.Source: Sanofi AventisSanofi-aventis announced today that the outcome of the long-term, 5-year trial of Lantus versus NPH been the progression of retinopathy people with type 2 diabetic, publish on-line in Diabetologia showed similar effects on retinopathy and overall safety in both treatment groups. This is the longest controlled study, open label ever reported by insulin glargine is.
Over Sanofi AventisSanofi – aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions order to improve the lives of people. Sanofi – : Sanofi-aventis is in Paris noted.